Weekly vs. Every-3-Week cisplatin: which is safer for head and neck cancer?

NCT ID NCT02994069

Ongoing Disease control Sponsor: Susanne Arnold Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether giving cisplatin chemotherapy weekly alongside radiation causes fewer severe side effects than the standard every-3-week schedule in people with head and neck cancer. About 80 participants will receive one of the two schedules. The study also looks at how oxidative stress markers relate to side effects. Results could help doctors choose a safer treatment plan.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Cisplatin (chemotherapy) given with radiation therapy
What this could lead to: If successful, this could show that weekly cisplatin is safer than the standard every-3-week schedule while still controlling the cancer.
What could go wrong: This is a small phase 2 trial with only 80 participants, so results may not apply to all patients. The study is also not testing a new drug, just a different dosing schedule.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARCINOMA, SQUAMOUS CELL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

carcinoma head and neck cancer Head and Neck Neoplasms head and neck squamous cell carcinoma squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARCINOMA, SQUAMOUS CELL HEAD AND NECK CANCER

Contacts and locations

Locations

University of Kentucky

Lexington, Kentucky, 40536, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.